At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
Sunitinib malatedrug
Likely dose
Sunitinib malate 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer
In Brief
A Phase 2 clinical trial evaluating Sunitinib malate for Carcinoma, Renal Cell. Completed, enrolled 120 participants across 15 sites in 6 countries.
Detailed Summary
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily regimen (once per day) for one year.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesArgentina, Australia, Brazil, Mexico, South Korea, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2006
Enrollment StartSep 2006
Primary CompletionApr 2009
TodayJul 2026
First PostedJun 20, 2006
Enrollment StartSep 1, 2006
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 20.0 years ago
Interventions
Sunitinib malatedrug
Sunitinib malate starting dose 37.5 mg daily continuous daily schedule